Arakoda, an 8-aminoquinolone antimalarial, was approved in 2018 for the prophylaxis of malaria in patients aged 18 years and older.

Individuals with recall related inquiries can contact Amneal Pharmaceuticals at (833) 582-0812 or via email at [email protected]. Adverse reactions should be reported to ...

The new vaccine is indicated for individuals who have been previously vaccinated with any COVID-19 vaccine and are 65 years or older, or 12 to 64 years of age with at least 1 underlying condition that ...

The approval was supported by data from the randomized, double-blind, placebo-controlled, phase 3 ARANOTE trial.

The FDA is expected to decide on treatments for multiple myeloma, NSCLC, melanoma, phenylketonuria, and 2 rare kidney diseases.

Findings seen in women with moderate-to-severe vasomotor symptoms associated with endocrine therapy for HR-positive breast cancer.

Inverse correlation seen for arterial flow mediated dilation with smoking frequency and amount of THC ingested.

The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) for ziftomenib as a treatment for adult patients with relapsed or refractory (R/R) acute myeloid ...

Patients who would benefit most from surgery and are least likely to benefit from continued medical therapy alone should be identified ...

It's not likely that shoppers will come across any fresh tomatoes from the recalled batch, according to the FDA.

Clinically relevant but not statistically significant improvement seen in anxiety and fatigue versus usual services.

A phase 1 trial, LUMINA, is currently underway and is evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of AMX0114 in approximately 48 patients with ALS.